FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.
What happened
FDA inspected Avaria's drug manufacturing facility in Cambridge, Ontario, from April 22 to 30, 2024. Investigators found the company did not test each incoming shipment of each ingredient lot for identity, including a high-risk ingredient where the USP test also detects hazardous impurities. FDA also found the company had not validated its manufacturing processes or qualified its equipment, and that its quality unit was not providing adequate oversight; the letter notes similar violations were cited in an August 3, 2023 warning letter.
What FDA found
The company did not test each incoming lot of each ingredient to confirm it is the right substance.
21 CFR 211.84(d)(1)For a high-risk ingredient, the company did not run the USP identity test that also detects hazardous impurities, so it could not show the ingredient was safe to use.
21 CFR 211.84(d)(1)The company had no data showing its manufacturing processes were validated or reproducible, and no data qualifying its equipment; its QA manager said such studies were not the firm's practice.
21 CFR 211.100(a)The quality unit did not verify that its testing methods give accurate, precise and reliable results.
21 CFR 211.194(a)(2)The company did not routinely calibrate equipment used to make, process, pack or hold drugs.
21 CFR 211.68(a)The company did not perform annual product reviews.
21 CFR 211.180(e)
What FDA wants
Respond in writing within 15 working days describing what you have done to fix the violations and prevent recurrence, or explain the delay and give a completion schedule. FDA also recommends engaging a qualified CGMP consultant to do a six-system audit before the firm seeks to resume making drugs for the U.S. market.
Who should pay attention
- brands that buy finished OTC drug products from this contract manufacturer
- U.S. importers and distributors of Canadian-made OTC drugs
- quality teams qualifying suppliers of over-the-counter drug products
This is a summary. Read the original letter on fda.gov.